Paclitaxel formulations: challenges and novel delivery options.

Area of Science:

• Pharmacology
• Nanotechnology
• Oncology

Background:

• Paclitaxel (PTX) is a potent broad-spectrum anti-cancer agent used for various cancers.
• Commercial PTX formulations (e.g., Taxol®) exhibit poor aqueous solubility and significant side effects.
• Extensive research has focused on developing cremophor-free and improved PTX formulations over three decades.

Purpose of the Study:

• To review challenges in paclitaxel formulation development.
• To discuss limitations of existing PTX formulations.
• To highlight novel approaches and clinical advancements in alternative PTX formulations.

Main Methods:

• Review of published research on paclitaxel nanocarrier systems.
• Analysis of various nanocarrier types: nanoparticles, liposomes, micelles, bioconjugates, and dendrimers.
• Examination of clinical trial progress and commercialized nanocarrier formulations.

Main Results:

• Nanocarrier systems enhance PTX solubility and encapsulation efficiency.
• These systems can overcome P-glycoprotein (P-gp) mediated efflux and reduce side effects.
• Several PTX nanocarrier formulations are in clinical trials or have been commercialized (e.g., Abraxane®, Lipusu, Genexol PM®).

Conclusions:

• Nanocarrier-based formulations represent a significant advancement in paclitaxel delivery.
• These novel formulations offer improved efficacy and safety profiles for cancer treatment.
• Continued development and clinical evaluation of PTX nanocarriers are crucial for optimizing cancer therapy.